Introduction
============

Obesity is closely associated with a series of health conditions, including type 2 diabetes mellitus (T2DM), cardiovascular disease, and even cancers that confer a higher risk of mortality. The current prevalence and trend data indicate that about 2 billion people globally are overweight and one third of these obese, and these conditions are linked to a variety of physical and psychosocial health concerns ([@B33]). Although it remains controversial, the American Medical Association (AMA) has declared obesity to be a disease ([@B3]). Some specialists have argued that obesity is not a disease, but a risk factor for other chronic diseases ([@B15]). Primary care physicians have also been reported to hold divergent opinions on whether obesity should be considered a risk factor or a disease ([@B10]). Clinically, some obese people without inflammation are sensitive to insulin and do not develop T2DM, whereas others with inflammation are resistant to insulin and develop T2DM. Therefore, a distinct classification into non-inflammatory/healthy obesity and inflammatory/unhealthy obesity has been independently suggested by multiple authors ([@B13]; [@B14]).

Although the concept of inflammatory obesity has yet to be commonly accepted, it has been highlighted with respect to possible mechanisms that cryopyrin/NLRP3 inflammasome-induced adipose macrophages in mice facilitate weight gain by upregulating monoamine oxidase A (MAOA), which degrades the catecholamine noradrenaline and hence decreases the levels of the critical lipolytic enzymes adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) ([@B7]).

In support of the inflammatory origin of obesity, both antibiotics and anti-inflammatory agents have been documented to exert weight-reducing effects by eradicating pathogenic infection and abrogating pro-inflammatory responses, respectively, as described in detail below.

Weight Reduction Using Antibiotics
==================================

The recent finding that the overgrowth and excessive metabolic activity of gut microbiota flora raise the risk of developing obesity and related metabolic disorders suggests that manipulating the dysbiotic gut microbiota population using various antimicrobial strategies may be beneficial for the management of obesity and the prevention of obesity-associated malfunctional conditions ([@B24]). Similarly, [@B2] have reviewed the effects of antibiotics on the gut microbiota of humans and animals and discussed the potential therapeutic use of antibiotics for weight loss in the former.

For example, it has been revealed that the conversion of white adipose tissue (WAT) to brown adipose tissue (BAT) is promoted by antibiotic treatment or in germ-free mice ([@B35]). Consequently, glucose tolerance and insulin sensitivity are improved in obese leptin-deficient (*ob*/*ob*) mice and mice fed with a high-fat diet (HFD). Conversely, these indices are reversed by recolonization of the antibiotic-treated or germ-free mice with microbes.

In another investigation, it was demonstrated that *Methanobrevibacter smithii* reduction and breath methane eradication by a 10-day antibiotic therapy regimen significantly decreases the serum levels of total cholesterol and low-density lipoprotein in prediabetic subjects with obesity, as well as leading to lower insulin and glucose levels ([@B23]).

Weight Reduction Using Anti-Inflammatory Agents
===============================================

Salicylate, an active metabolite of the non-steroidal anti-inflammatory drug (NSAID) aspirin, can reverse HFD-induced obesity and insulin resistance by the inhibition of nuclear factor kappa B (NF-κB) ([@B37]). Exposure to the anti-inflammatory agents aspirin or statins is associated with weight loss in T2DM patients ([@B5]). The immunosuppressant rapamycin also exhibits a weight-reducing effect, normalizing serum leptin and alleviating obesity in aged rats ([@B32]), perhaps by inhibiting NF-κB activation and repressing pro-inflammatory signaling ([@B9]).

Surprisingly, the antimalarial drug artemisinin and the antidiabetic drug metformin have been demonstrated to display an unexpected weight-reducing effect (see below). Interestingly, artemisinin was previously found to inhibit NF-κB signaling ([@B1]). Similarly, metformin was also recently shown to suppress signal transducer and activator of transcription (STAT) signaling in addition to NF-κB signaling ([@B31]).

In the obese mouse model described above ([@B7]), the deletion of cryopyrin/NLRP3 in the inflammation-induced adipose macrophages was found to restore noradrenaline-induced lipolysis by downregulating growth differentiation factor-3 (GDF3). Furthermore, the deletion of GDF3 in the inflammasome-activated macrophages improved lipolysis by decreasing MAOA levels. The inhibition of MAOA reverses noradrenaline reduction and restores lipolysis, leading to increased ATGL and HSL levels in adipose tissue.

Weight Reduction Using Mitochondrial Uncouplers
===============================================

Although the increased lipid degradation upon inflammasome inhibition can be reasonably explained as described above, the mechanism of how fatty acids be degraded completely remains unknown. Nevertheless, it can be deduced that the mitochondrial dynamics from a greater number of mitochondria in BAT to fewer mitochondria in WAT should affect the body weight, i.e., obese or lean, because the sequential β-oxidation of fatty acids principally occurs within the mitochondria.

As a mitochondrial uncoupler that disassociates electron transport from oxidative phosphorylation through leakage of protons across the inner mitochondrial membrane, 2,4-dinitrophenol (DNP) has been widely used as an effective weight loss drug since the early 1930s ([@B12]). The controlled release of DNP not only reduces hypertriglyceridemia, insulin resistance, hepatic steatosis, and diabetes in the HFD-induced obesity rat model, but also normalizes plasma transaminase levels, ameliorates liver fibrosis, and improves hepatic protein synthesis function in a methionine/choline-deficient rat model of non-alcoholic steatohepatitis ([@B11]; [@B28]).

Weight Reduction Using Other Weight-Reducing Drugs With Unknown Mechanisms
==========================================================================

Apart from antibiotics, anti-inflammatory agents, and mitochondrial uncouplers, a plethora of other structurally unrelated compounds with unknown mechanisms of action, such as the dimethylbiguanide metformin, the trihydroxystilbene resveratrol, and the sesquiterpene artemisinin, also exert some degree of weight-reducing effects.

In one study, the mean weight loss in the metformin-treated group over 6 months was found to be 5.8 ± 7.0 kg, whereas untreated controls (non-diabetic individuals with obesity) gained 0.8 ± 3.5 kg on average ([@B34]). In particular, patients with severe insulin resistance lost significantly more weight compared with insulin-sensitive patients.

In rats fed a resveratrol-containing diet, it was found that abdominal adipose accumulation was markedly prevented, fat metabolism and sparing actions for carbohydrates and proteins were partially enhanced, and adipose carnitine palmitoyltransferase mRNA levels were significantly elevated ([@B25]).

C3H10T1/2 cells treated with artemether, an artemisinin derivative, were found to display a typical thermogenic morphology: smaller adipocytes with plurilocular lipid droplets ([@B21]). Mitochondrial biogenesis-related genes such as *UCP1*, *PGC-1α*, *PRDM16*, and *CytC* were also upregulated by artemether in a dose-dependent manner.

Suggested Mechanism Underlying Mitochondria-Dependent Adipogenesis and Adipolysis
=================================================================================

To account for weight gain and weight loss in a mitochondria-dependent manner, we suggest here a mechanism that we refer to as "high/low-level nitric oxide (NO)-switched adipogenesis/adipolysis," in which a pro-inflammatory signal upregulates *NOS2*/inducible nitric oxide synthase (iNOS) to trigger a potent NO burst, block mitochondrial respiration, and facilitate lipogenesis, whereas an anti-inflammatory response upregulates *NOS3*/endothelial nitric oxide synthase (eNOS) to maintain mild NO release, prompt mitochondrial biogenesis, and enhance lipolysis.

In terms of the evidence supporting such a mechanism, it has been established that high levels of NO inhibit cell respiration, whereas slow and small-scale NO release stimulates mitochondrial biogenesis by binding to cytochrome *c* oxidase (COX) in mitochondria ([@B26]). For example, calorie restriction enhances mitochondrial biogenesis, which is initiated by eNOS-derived low-level NO ([@B27]). However, it remains unknown whether metformin, resveratrol, or artemisinin can also generate NO, interrupt electron transport, trigger mitochondrial biogenesis, or accelerate energy expenditure.

Emerging Evidence Supporting the Putative Weight-Reducing Mechanism
===================================================================

Through mitochondrial uncoupling, DNP leads to the synchronous increases of adenosine monophosphate (AMP) and oxidized nicotinamide adenine dinucleotide (NAD^+^) levels ([@B18]). Increases in AMP and NAD^+^ levels can activate AMP-activated kinase (AMPK) and NAD^+^-dependent deacetylase sirtuin-1 (SIRT1), respectively, which in turn activate peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) for mitochondrial biogenesis ([@B29]; [@B19]).

Although metformin was previously identified as a classic activator of AMPK ([@B22]), it can also target mitochondria to inhibit NADH dehydrogenase and adenosine triphosphate (ATP) synthase, thereby triggering mitochondrial biogenesis ([@B6]). Additionally, the inhibition of the mitochondrial respiratory function by metformin results in the upregulation of fibroblast growth factor 21 (FGF21), which also possesses anti-obesity and anti-diabetes effects ([@B16]).

Resveratrol is conventionally classified as an activator of SIRT1 ([@B4]), but it can also induce mitochondrial biogenesis in a manner dependent upon NO production, cyclic guanosine monophosphate (cGMP) biosynthesis, heme oxygenase 1 (HO-1) activation, and carbon monoxide (CO) generation ([@B17]). Actually, resveratrol has been previously reported to induce HO-1 expression via nuclear erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) activation in neuronal PC12 cells ([@B8]). HO-1 induction can reduce the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) from adipocytes and macrophages by inhibiting the activation of inflammatory signaling molecules including NF-κB and Janus kinase (JNK) ([@B36]). However, the exact mitochondrial target of resveratrol has yet to be identified.

By targeting cytochrome c1 and NADH dehydrogenase \[ubiquinone\] flavoprotein 1, artemisinin resembles the NO donor nitroglycerin and exerts anti-inflammatory effects, downregulates *NOS2*/iNOS expression, maintains stable NO release, and augments adipose mitochondrial functions that necessitate adipolysis for weight loss (Gao et al., unpublished). Interestingly, it was found that NO generation is well-correlated with ATP production, *NOS3*/eNOS upregulation, and mitochondrial biomarker overexpression upon treatment with artemisinin or nitroglycerin, suggesting that artemisinin- or nitroglycerin- generated NO prompts adipose degradation and energy expenditure by triggering mitochondrial biogenesis.

It has recently been reported that AMPK catalyzes the phosphorylation of JAK and inhibits JAK/STAT signaling ([@B30]), which implies that mitochondrial uncouplers also resemble antibiotics or anti-inflammatory agents to exert anti-inflammatory effects by activating AMPK. Conversely, it was also shown that AMPK activates eNOS via the AMPK→Rac1→Akt→ eNOS pathway ([@B20]), thereby indicating that antibiotics and anti-inflammatory agents also result in mitochondrial uncoupling, by which they influence mitochondria through the inhibition of iNOS-generated high-level NO and the activation of eNOS-synthesized low-level NO.

Accordingly, mitochondrial dysfunction may lead to inflammation because a mitophagy/autophagy blockade causes the accumulation of damaged and reactive oxygen species (ROS)-generating mitochondria, which in turn activates the NLRP3 inflammasome to sense mitochondrial dysfunction. This pathway would explain the possible association of mitochondrial damage with inflammatory diseases ([@B38]).

In summary, the roles of antibiotics, anti-inflammatory agents, and mitochondrial uncouplers in combating obesity are linked by the common effects of increasing eNOS-derived low-level NO to enter mitochondria, target mitochondrial complexes, and interfere with mitochondrial functions, which results in enhanced mitochondrial biogenesis, increased fatty acid oxidation, and accelerated weight reduction (**Figure [1](#F1){ref-type="fig"}**).

![Mitochondrial biogenesis driven by calorie restriction (CR), anti- inflammatory agents, and energy uncouplers by turning off/on the iNOS/eNOS switch. ART, artemisinin; ASP, aspirin; DNP, 2,4-dinitrophenol; MET, metformin; RAP, rapamycin; RSV, resveratrol. CI--CV represent mitochondrial complexes I--V. The red arrows represent activation or upregulation, and the black arrows represent inactivation or downregulation. While low-level NO transiently binds to CIV to trigger mitochondrial biogenesis, high-level NO permanently binds to CIV to block mitochondrial respiration.](fphar-09-00069-g001){#F1}

The above mechanistic definition of the concept of inflammatory obesity is anticipated to assist in the discovery of pathology-based weight-reducing drugs, which will be beneficial for combating obesity and therefore mitigating the effects of obesity-related metabolic disorders in the near future.
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